Ovarian response to 150 mu g corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373818" target="_blank" >RIV/00216208:11130/17:10373818 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/17:10373818

Výsledek na webu

<a href="https://doi.org/10.1016/j.rbmo.2017.02.012" target="_blank" >https://doi.org/10.1016/j.rbmo.2017.02.012</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rbmo.2017.02.012" target="_blank" >10.1016/j.rbmo.2017.02.012</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Ovarian response to 150 mu g corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study

Popis výsledku v původním jazyce

The incidence of low (&lt;6 oocytes) and high (&gt;18 oocytes) ovarian response to 150 mu g corifollitropin alfa in relation to anti-Mullerian hormone (AMH) and other biomarkers was studied in a multi-centre (n = 5), multi-national, prospective, investigator-initiated, observational cohort study. Infertile women (n = 212), body weight &gt;60 kg, underwent controlled ovarian stimulation in a gonadotrophin-releasing hormone-antagonist multiple-dose protocol. Demographic, sonographic and endocrine parameters were prospectively assessed on cycle day 2 or 3 of a spontaneous menstruation before the administration of 150 mu g corifollitropin alfa. Serum AMH showed the best correlation with the number of oocytes obtained among all predictor variables. In receiver-operating characteristic analysis, AMH at a threshold of 0.91 ng/ml showed a sensitivity of 82.4%, specificity of 82.4%, positive predictive value 52.9% and negative predictive value 95.1% for predicting low response (area under the curve [AUC], 95% CI; P-value: 0.853, 0.769-0.936; &lt;0.0001). For predicting high response, the optimal threshold for AMH was 2.58 ng/ml, relating to a sensitivity of 80.0%, specificity 82.1%, positive predictive value 42.5% and negative predictive value 96.1% (AUC, 95% CI; P-value: 0.871, 0.787-0.955; &lt;0.0001). In conclusion, patients with serum AMH concentrations between approximately 0.9 and 2.6 ng/ml were unlikely to show extremes of response. (C) 2017 Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.

Název v anglickém jazyce

Ovarian response to 150 mu g corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study

Popis výsledku anglicky

The incidence of low (&lt;6 oocytes) and high (&gt;18 oocytes) ovarian response to 150 mu g corifollitropin alfa in relation to anti-Mullerian hormone (AMH) and other biomarkers was studied in a multi-centre (n = 5), multi-national, prospective, investigator-initiated, observational cohort study. Infertile women (n = 212), body weight &gt;60 kg, underwent controlled ovarian stimulation in a gonadotrophin-releasing hormone-antagonist multiple-dose protocol. Demographic, sonographic and endocrine parameters were prospectively assessed on cycle day 2 or 3 of a spontaneous menstruation before the administration of 150 mu g corifollitropin alfa. Serum AMH showed the best correlation with the number of oocytes obtained among all predictor variables. In receiver-operating characteristic analysis, AMH at a threshold of 0.91 ng/ml showed a sensitivity of 82.4%, specificity of 82.4%, positive predictive value 52.9% and negative predictive value 95.1% for predicting low response (area under the curve [AUC], 95% CI; P-value: 0.853, 0.769-0.936; &lt;0.0001). For predicting high response, the optimal threshold for AMH was 2.58 ng/ml, relating to a sensitivity of 80.0%, specificity 82.1%, positive predictive value 42.5% and negative predictive value 96.1% (AUC, 95% CI; P-value: 0.871, 0.787-0.955; &lt;0.0001). In conclusion, patients with serum AMH concentrations between approximately 0.9 and 2.6 ng/ml were unlikely to show extremes of response. (C) 2017 Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10600 - Biological sciences

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Reproductive BioMedicine Online

ISSN

1472-6483

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

534-540

Kód UT WoS článku

000401128200013

EID výsledku v databázi Scopus

2-s2.0-85014662627